They are:
- Humira — $21.4 billion
- Eliquis — $9.9 billion
- Enbrel — $8.1 billion
- Stelara — $6.6 billion
- Keytruda — $6.5 billion
- Trulicity — $6.5 billion
- Januvia — $6 billion
- Xarelto — $6 billion
- Biktarvy — $5.1 billion
- Remicade — $4.7 billion
- Opdivo — $4.4 billion
- Rituxan — $4.3 billion
- Lantus Solostar — $4.3 billion
- Symbicort — $3.9 billion
- Jardiance — $3.9 billion
- Genvoya — $3.8 billion
- Tecfidera — $3.8 billion
- Vyvanse — $3.7 billion
- Victoza 3-pak — $3.6 billion
- Ibrance — $3.6 billion
Find the full report here.
More articles on pharmacy:
CVS HealthHub rollout resumes
Merck bets on one-shot vaccine
Virginia pharmacy school files suit against accreditation agency, calls process ‘bizarrely contradictory and Kafkaesque’
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.